MetaCap

NeuroSense Therapeutics (NRSN) vs Xenetic Biosciences (XBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xenetic Biosciences is the larger company by market cap ($3.3 million vs $3.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NRSN-66.49%XBIO-36.65%
+3%-34%-70%
Oct 7, 20261 yearNov 20, 2026
NRSN-65.03%XBIO-34.27%
+3%-33%-68%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NRSN versus XBIO key metrics
MetricNRSNXBIO
Share price$1.28$1.40
Market cap$3.19M$3.28M
1-day change+1.59%-9.09%
EPS (TTM)$-47.10$-1.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.98M
Revenue growth (YoY)—+19.04%
Net income (latest FY)$-11.13M$-2.68M
Operating margin—-95.23%
Net margin—-90.07%
52-week high$24.80$4.94
52-week low$1.10$1.25
Distance from 52-week high-94.84%-71.65%
Analyst consensusstrong_buy—
Avg. price target upside+7503.91%—
Average volume31.57K73.30K
Shares outstanding2.49M2.34M
Employees172
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About NeuroSense Therapeutics

NRSN stock →

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Xenetic Biosciences

XBIO stock →

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

NRSN vs XBIO FAQ

Which is bigger, NeuroSense Therapeutics or Xenetic Biosciences?

Xenetic Biosciences (XBIO) is larger, with a market capitalization of $3.28M compared with $3.19M for NeuroSense Therapeutics (NRSN).

Are NeuroSense Therapeutics and Xenetic Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons